Cancer News
Cancer Education and Research Institute® (CERI)'s Cancer Education Programs
Our Team of cancer experts at Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
Cancer Vaccines
New cancer vaccine led to significant tumor shrinkage in mice
Aygün Sahin, MSc, PhD | CEO, President, and Cancer Lead, Cancer Education and Research Institute (CERI)
National Institute of Allergy and Infectious Diseases (NIAID) researchers developed a cancer vaccine, called SNAPvax.
SNAPvax is a self-assembling nanoparticle vaccine that *links* tumor antigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a).
Toll-like receptors (TLRs), are mainly expressed on antigen-presenting cells, such as macrophages or dendritic cells. Their signaling activates antigen-presenting cells to provoke innate immunity and to establish adaptive immunity.
NIH researchers treated tumor-bearing mice with this vaccine in two ways: 1) Subcutaneously (SNP-SC), and 2) Intravenously (SNP-IV).
Both routes generated antigen-specific CD8+ T cells that infiltrated tumors.
However, only the IV delivery triggered the body’s innate immune system by inducing type I interferon. These interferons are a protein animal cells release in response to viruses.
The researchers found that this innate immune response changed the tumor microenvironment, which prevented the cancerous cells from suppressing T cell action.
The experimental vaccine, SNAPvax, was designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center (VRC) together with collaborators from Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland.
Vaccitech announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023.
CONCLUSION: The generation of tumor-specific, tumor-killing CD8+ T cells combined with remodeling of the tumor microenvironment is a promising approach for tumor immunotherapy.
SNAPvax is a self-assembling nanoparticle vaccine that *links* tumor antigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a).
Toll-like receptors (TLRs), are mainly expressed on antigen-presenting cells, such as macrophages or dendritic cells. Their signaling activates antigen-presenting cells to provoke innate immunity and to establish adaptive immunity.
NIH researchers treated tumor-bearing mice with this vaccine in two ways: 1) Subcutaneously (SNP-SC), and 2) Intravenously (SNP-IV).
Both routes generated antigen-specific CD8+ T cells that infiltrated tumors.
However, only the IV delivery triggered the body’s innate immune system by inducing type I interferon. These interferons are a protein animal cells release in response to viruses.
The researchers found that this innate immune response changed the tumor microenvironment, which prevented the cancerous cells from suppressing T cell action.
The experimental vaccine, SNAPvax, was designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center (VRC) together with collaborators from Vaccitech North America, a clinical-stage biopharmaceutical company in Baltimore, Maryland.
Vaccitech announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023.
CONCLUSION: The generation of tumor-specific, tumor-killing CD8+ T cells combined with remodeling of the tumor microenvironment is a promising approach for tumor immunotherapy.
References:
- Baharom, F. et al. Volume 185, ISSUE 23, P4317-4332.e15, November 10, 2022 (accessed 11/15/2022)
- Experimental Cancer Vaccine Shows Promise in Animal Studies (accessed 11/15/2022)
- New cancer vaccine successfully boosts immune system, shrinks tumors in mice (accessed 11/15/2022)
- Kaisho, T and Akira S. Toll-like receptor function and signaling. Journal of Allergy and Clinical Immunology. Volume 117, Issue 5, May 2006, Pages 979-987, (accessed 11/15/2022)
Do you need help with cancer diagnosis?
Please fill the application form on our CERI Personalized Patient Program page - we CAN help you!
#Empowermentagainstcancer™ #CERICancerEducation #CERICares #CancerSimplified
#cancer #glioblastoma #gbm #glioblastomatherapy #GBMtherapy #glioblastomatreatment #GBMtreatment #cancereducation #cancerresearch #cancertreatment #canceredinstitute
GET YOUR FREE ARTICLE: Make sure to get your free article as our gift to you! Go to: canceredinstitute.org/ceri-simplified-cancer-research-articles
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
- INSTAGRAM: instagram.com/canceredinstitute
- FACEBOOK: facebook.com/canceredinstitute
- Twitter: twitter.com/canceredinst
- LinkedIn: linkedin.com/company/canceredinstitute
You might also like:
|
|
|
Disclaimer: We can not assume responsibility of misinterpretation of content.
Please donate to support our program - help us save MORE lives!
